Funding for this research was provided by:
Instituto de Salud Carlos III (PI160235)
the Leonard Wolfson Experimental Neurology Centre
Wellcome Trust Multi-User Equipment Grant
UK Dementia Research Institute
European Research Council
Received: 9 February 2018
Accepted: 11 October 2018
First Online: 3 November 2018
Ethics approval and consent to participate
: The study was approved by the Hospital Clinic of Barcelona ethics committee (HCB/2012/7476) and all subjects gave written informed consent.
: Not applicable.
: HZ has served on advisory boards for Roche Diagnostics and Eli Lilly, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, Sweden. NCF has received fees (paid to University College London) for consultancy from Eli Lilly, Novartis, Sanofi, Roche/Genentech, and GlaxoSmithKline, and for serving on a Data Monitoring Committee for Biogen. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.